KR20020047301A - 소듐2-(4,6-디메틸-피리미딘-2-일옥시)-3-(2-(3,4-디메톡시페닐)에톡시)-3,3-디페닐프로피오네이트 및 엔도텔린길항제로서의 그의 용도 - Google Patents

소듐2-(4,6-디메틸-피리미딘-2-일옥시)-3-(2-(3,4-디메톡시페닐)에톡시)-3,3-디페닐프로피오네이트 및 엔도텔린길항제로서의 그의 용도 Download PDF

Info

Publication number
KR20020047301A
KR20020047301A KR1020027005457A KR20027005457A KR20020047301A KR 20020047301 A KR20020047301 A KR 20020047301A KR 1020027005457 A KR1020027005457 A KR 1020027005457A KR 20027005457 A KR20027005457 A KR 20027005457A KR 20020047301 A KR20020047301 A KR 20020047301A
Authority
KR
South Korea
Prior art keywords
sodium
dimethoxyphenyl
ethoxy
diphenylpropionate
compound
Prior art date
Application number
KR1020027005457A
Other languages
English (en)
Korean (ko)
Inventor
롤프 얀센
Original Assignee
스타르크, 카르크
바스프 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타르크, 카르크, 바스프 악티엔게젤샤프트 filed Critical 스타르크, 카르크
Publication of KR20020047301A publication Critical patent/KR20020047301A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020027005457A 1999-10-27 2000-10-17 소듐2-(4,6-디메틸-피리미딘-2-일옥시)-3-(2-(3,4-디메톡시페닐)에톡시)-3,3-디페닐프로피오네이트 및 엔도텔린길항제로서의 그의 용도 KR20020047301A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19951671A DE19951671A1 (de) 1999-10-27 1999-10-27 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist
DE19951671.5 1999-10-27
PCT/EP2000/010202 WO2001030767A1 (de) 1999-10-27 2000-10-17 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionsäure-natriumsalz und seine verwendung als endothelinantagonist

Publications (1)

Publication Number Publication Date
KR20020047301A true KR20020047301A (ko) 2002-06-21

Family

ID=7927001

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027005457A KR20020047301A (ko) 1999-10-27 2000-10-17 소듐2-(4,6-디메틸-피리미딘-2-일옥시)-3-(2-(3,4-디메톡시페닐)에톡시)-3,3-디페닐프로피오네이트 및 엔도텔린길항제로서의 그의 용도

Country Status (17)

Country Link
EP (1) EP1228047A1 (de)
JP (1) JP2003512460A (de)
KR (1) KR20020047301A (de)
CN (1) CN1384822A (de)
AU (1) AU1272701A (de)
BG (1) BG106700A (de)
BR (1) BR0015112A (de)
CA (1) CA2389012A1 (de)
CZ (1) CZ20021485A3 (de)
DE (1) DE19951671A1 (de)
HU (1) HUP0203476A3 (de)
IL (1) IL149312A0 (de)
MX (1) MXPA02004071A (de)
NO (1) NO20021986D0 (de)
SK (1) SK5962002A3 (de)
TR (1) TR200201169T2 (de)
WO (1) WO2001030767A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101006076B (zh) 2004-06-24 2010-09-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

Also Published As

Publication number Publication date
NO20021986L (no) 2002-04-26
BR0015112A (pt) 2002-10-29
JP2003512460A (ja) 2003-04-02
NO20021986D0 (no) 2002-04-26
HUP0203476A2 (en) 2003-05-28
CA2389012A1 (en) 2001-05-03
BG106700A (en) 2003-02-28
HUP0203476A3 (en) 2003-07-28
MXPA02004071A (es) 2002-10-11
WO2001030767A1 (de) 2001-05-03
DE19951671A1 (de) 2001-05-03
TR200201169T2 (tr) 2002-09-23
IL149312A0 (en) 2002-11-10
AU1272701A (en) 2001-05-08
CZ20021485A3 (cs) 2003-06-18
SK5962002A3 (en) 2002-09-10
CN1384822A (zh) 2002-12-11
EP1228047A1 (de) 2002-08-07

Similar Documents

Publication Publication Date Title
JP4234344B2 (ja) スルホンアミド含有複素環化合物
JP3866041B2 (ja) スルホンアミド含有インドール化合物
CN1930127B (zh) 用于合成cxcr4拮抗剂的方法
NZ286711A (en) Macrocyclic polyamine derivatives and pharmaceutical compositions thereof
JPH08269060A (ja) ヘテロ環化合物、その製造方法およびそれを含有する医薬品
CZ289787A3 (cs) Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi
CA2121391A1 (en) Indoloylguanidine derivatives
FR2883285A1 (fr) Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl) -1,2,3,6-tetrahudro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique
BR112013032306B1 (pt) derivados de indanona, método de preparação dos mesmos, composições farmacêuticas e uso dos mesmos para prevenção ou tratamento de doenças virais
WO2011018101A1 (en) Lenalidomide salts
CN112624983B (zh) 一种含烷基结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
US20050043304A1 (en) Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
JP2007516950A (ja) プロスタグランジンｅ２アゴニストまたはアンタゴニストであるオルニチン誘導体
JPH0317078A (ja) ８‐置換４‐（ヘテロサイクリルメチルアミノ）‐キノリン
KR20020047301A (ko) 소듐2-(4,6-디메틸-피리미딘-2-일옥시)-3-(2-(3,4-디메톡시페닐)에톡시)-3,3-디페닐프로피오네이트 및 엔도텔린길항제로서의 그의 용도
MXPA02000033A (es) Polimorfos de un diclorhidrato cristalino de azobiciclo (2, 2, 2)oct-3-ilamina y sus composiciones farmaceuticas.
EP1270569A1 (de) Substituierte tryptophanderivate
JPH0327363A (ja) チオウラシル誘導体
WO2016107541A1 (zh) 吡咯酰胺类化合物及其制备方法与用途
KR100464526B1 (ko) 나트륨-수소 교환체 타입 1 억제제 결정
JP2006500337A (ja) 塩酸ベナゼプリルの結晶多形形態および非晶質形態
KR20100020513A (ko) 발사르탄을 제조하는데 효과적인 발사르탄 염 제조 방법
JP2011513292A (ja) 新規な結晶形
CA2117075A1 (en) Quinazoline derivatives and their preparation
JPH083162A (ja) イミダゾピリジン誘導体及びその製法

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E601 Decision to refuse application